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The erythropoietic porphyrias, erythropoietic proto-
porphyria and congenital erythropoietic porphyria,
result from germline mutations in the ferrochelatase
gene and uroporphyrinogen III synthase gene,
respectively. Both conditions normally present in
childhood but rare cases with onset past the age of
40 y have been reported. Here we show that late-
onset erythropoietic protoporphyria can be caused
by deletion of the ferrochelatase gene in hematopoie-
tic cells with clonal expansion as part of the myelo-
dysplastic process. This is the ®rst direct
demonstration of porphyria produced by an acquired
molecular defect restricted to one tissue. Some other
cases of late-onset erythropoietic porphyria may be
explained by a similar mechanism. Key words: dele-
tion/erythropoietic protoporphyria/FECH/ferrochelatase/
myelodysplasia. J Invest Dermatol 117:1647±1649, 2001
T
he porphyrias are disorders that result from over-
production of heme precursors caused by partial
de®ciencies in enzymes of heme biosynthesis. In all
porphyrias, apart from the sporadic form of porphyria
cutanea tarda, the enzyme de®ciencies are present in
all tissues and caused by mutations in the corresponding genes that
are inherited through the germline to produce diseases with
autosomal dominant or recessive patterns of inheritance (Kappas et
al, 1995). In the erythropoietic porphyrias, congenital erythro-
poietic porphyria (CEP) (Fritsch et al, 1997; Desnick et al, 1998)
and erythropoietic protoporphyria (EPP) (Todd, 1994), the bone
marrow is the main site of overproduction of heme precursors.
Patients with CEP are homoallelic or heteroallelic for mutations
in the uroporphyrinogen III synthase (UROS) gene (Desnick et al,
1998) whereas clinical manifestation of EPP, a low-penetrance
autosomal dominant disorder (Went and Klasen, 1984), appears to
require a severe mutation in the ferrochelatase (FECH) gene on
one allele and a low expression ferrochelatase allelic variant, which
is common in the general population, on the other (Gouya et al,
1999). Together these decrease ferrochelatase activity to the 20%±
30% of normal found in clinically overt EPP. Both conditions
normally present in childhood with symptoms caused by photo-
sensitization of the skin by porphyrins (Todd, 1994; Fritsch et al,
1997) but rare, late-onset forms of each disorder in which
symptoms do not appear until after the age of 40 y have been
reported (Murphy et al, 1985, 1995; Fallon et al, 1989; Lim et al,
1992; Fritsch et al, 1997). In some of these patients, disorders
clinically and biochemically resembling EPP (Lim et al, 1992) or
CEP (Yamauchi and Kushibi, 1992; Ibbotson et al, 1998) have
developed in association with the myelodysplastic syndrome
(MDS). Molecular investigation of these cases has not been
reported. The 45 kb FECH gene is located at chromosome
18q21.3 (Brenner et al, 1992). Here we show that a deletion of one
allele of this gene that is restricted to hematopoietic cells can cause
late-onset EPP in MDS and suggest that somatic mutation in
hematopoietic cell lineages may provide a complete or partial
explanation for the pathogenesis of some other cases of late-onset
erythropoietic porphyrias.
MATERIALS AND METHODS
Patient A 51-y-old man presented with a 3 mo history of
photosensitivity, dyspnoea, and lethargy. He described a severe burning
sensation in the skin of his forearms and hands within minutes of
exposure to the sun with subsequent erythema, edema, and soreness that
lasted several days. His face was affected on one occasion only.
Examination showed a resolving erythematous eruption and edema over
the dorsal aspects of both hands and forearms sparing the area covered by
his watch with diffuse thickening of the skin over the interphalangeal
joints. He had a past history of tuberculosis as a child and alcohol abuse
but had been teetotal for 15 y; there was no evidence for exposure to
other toxic chemicals. Biochemical investigation showed increased
erythrocyte protoporphyrin at 11.9 mmol per liter (normal, 0.4±1.7 mmol
per liter) that was predominantly in the free form not complexed with
zinc, increased plasma porphyrin (86 nmol per liter; normal less than
10 nmol per liter), and normal urinary and fecal porphyrin
concentrations. This pattern of abnormalities con®rmed the clinical
diagnosis of late-onset EPP. Histologic examination of a skin biopsy
taken from the back of the hand showed extensive proliferation of
hyaline-like material positive to periodic acid±Schiff stain in and around
super®cial dermal blood vessels, characteristic of cutaneous porphyria.
Haematologic examination showed a peripheral blood pancytopenia
(hemoglobin, 7.4 g per dl; leukocytes, 3.5 3 109 per liter; platelets,
61 3 109 per liter) and a hypercellular bone marrow with excess
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myeloblasts and ring sideroblasts consistent with a diagnosis of refractory
anemia with excess blasts in transformation.
Molecular investigation Genomic DNA from bone marrow,
peripheral blood leukocytes, and skin was extracted by standard
procedures. All 11 exons of the FECH gene with 20±100 bp of ¯anking
sequence and 140 bp 5¢ to exon 1 were ampli®ed by the polymerase
chain reaction (PCR) using previously described primers (Rufenacht et
al, 1998) without G±C clamps. PCR-ampli®ed double-stranded DNA
was puri®ed and sequenced in forward and reverse orientations using an
Applied Biosystems model 377 automated sequencer as described
previously (Whatley et al, 1999). Haplotyping, using single nucleotide
polymorphisms within the FECH gene, was carried out as described
previously (Gouya et al, 1999). Microsatellite allele ratios were measured
using ¯uorescence-labeled PCR primers and an Applied Biosystems
model 373 automated sequencer with Genotyper software (PE Applied
Biosystems, Warrington, U.K.).
Other methods Bone marrow cytogenetic studies were carried out
by standard procedures. Fluorescence in situ hybridization (FISH) with
whole chromosome 18 paint was carried out according to the
manufacturer's instructions (Cambio, Cambridge, U.K.). Aspirated bone
marrow cells were sorted by ¯ow cytometry (FACS 440; Becton
Dickinson, Oxford, U.K.) according to the presence or absence of
porphyrin-induced auto¯uorescence, using excitation by a laser
producing beams at 351 nm and 363 nm and an emission wavelength of
greater than 620 nm.
RESULTS
Identi®cation of abnormal bone marrow karyotype Bone
marrow cytogenetic studies showed a complex abnormal
karyotype: 44, XY, ±2, ±5, ±7, del(9) (q21q34), ±12, ±12, ±16, ±
17, del(18) (q12q23 or q11.2q22), +5 mar (Fig 1). FISH
con®rmed an 18q deletion that included the region (18q21.3)
containing the FECH gene (Fig 1). Chromosomes 1, 3, 9, 10, and
11 that carry the other enzymes of heme biosynthesis appeared
normal.
Demonstration of FECH haplode®ciency in bone
marrow Bone marrow cells were sorted by ¯ow cytometry
into major non¯uorescent and minor (21% of total cells) ¯uorescent
populations. Morphologic examination of cytospin preparations
showed that the minor fraction was enriched with late normoblasts.
To demonstrate loss of the region of one FECH allele in
hematopoietic but not other cells, the allele ratios of a
microsatellite marker (D18S858) adjacent to the FECH locus
(Wang et al, 1999) were measured in genomic DNA from bone
marrow, ¯uorescent and non¯uorescent bone marrow fractions,
peripheral blood leukocytes, and skin. Table I shows almost
complete loss of heterozygosity in total and fractionated bone
marrow, indicating the presence of a single, dominant neoplastic
clone containing the 18q deletion, and some loss of heterozygosity
in peripheral blood leukocytes ± an observation that is consistent
with the expected noninvolvement of lymphoid cells in the
myelodysplastic process (Heaney and Golde, 1999).
Demonstration that the remaining FECH allele in bone
marrow is normal Because one null FECH allele does not
normally lead to overproduction of suf®cient porphyrin by
erythroid cells to cause photosensitivity (Gouya et al, 1999), we
examined the other allele for any point mutation that might
decrease enzyme activity and for a haplotype de®ned by intragenic
single nucleotide polymorphisms [±251G IVS1±23T] that is
strongly associated with a low expression ferrochelatase allele in
France (Gouya et al, 1999) and was present in 97 of 98 unrelated
British patients with clinically overt EPP that we have haplotyped
(Mason N, Whatley S, Elder G: unpublished data). The sequence
was identical to the reported sequence (HGMP GenBank accession
number AJ250235) except for one nucleotide in exon 8 (c798 G
> C; P166P). Sequencing DNA from the patient's skin showed that
he was heterozygous at this site, thus allowing direct con®rmation
of loss of one FECH allele in hematopoietic cells (Table I).
Haplotyping of DNA from the patient's skin showed that he was
homozygous for the haplotype [±251A IVS1±23C] that is not
associated with low expression of ferrochelatase (Gouya et al, 1999).
Thus we could ®nd no evidence to indicate that the remaining
FECH allele was abnormal.
DISCUSSION
Investigation of this patient shows that deletion of one FECH allele
in hematopoietic cells can lead to the late onset of a form of EPP
that is otherwise clinically and biochemically indistinguishable from
Figure 1. Bone marrow cytogenetic studies reveal abnormal
karyotype with deletion of 18q. (a) Abnormal karyotype in
hematopoietic cells. (b) FISH with chromosome 18 paint; arrows show
intact and partially deleted 18q chromosomes.
Table I. Allele ratios show loss of heterozygositya
Tissue D18S858 FECH
Skin 1.0 1.0
Peripheral blood leukocytes 0.62 ND
Bone marrow 0.15 ND
Non-¯uorescent cell fraction 0.13 0.24
Fluorescent cell fraction 0.06 0.12
aAllele ratios have been adjusted assuming that the ratio in genomic DNA from
skin is 1.0. Experimentally determined ratios were 1.3 for D18S858
(207 bp:213 bp) and 2.2 for an intragenic FECH polymorphism (798C:798G).
ND, not done.
1648 APLIN ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
the inherited disease. Overproduction of protoporphyrin from
erythroid cells in suf®cient quantity to produce photosensitization
does not normally occur in EPP in the absence of a low expression
ferrochelatase allele trans to the null allele (Gouya et al, 1999). In
our patient this did not appear to be the case, though the presence
of a mutation leading to impaired expression, but lying outside the
regions that we sequenced, cannot be excluded.
If the single FECH gene in our patient was expressed at normal
levels, our ®ndings suggest either that haplode®ciency alone may
lead to overproduction of protoporphyrin when erythropoiesis is
abnormal as in MDS or that ferrochelatase activity is impaired in at
least some erythroid cells in MDS. Thus, the dysplastic erythropoi-
esis with ring sideroblasts present in our patient may have decreased
ferrochelatase activity in bone marrow below the 50% expected
from haplode®ciency alone; for example, damage by iron to
mitochondrial membranes might impair ferrochelatase function
either directly or indirectly by decreasing iron transfer from the
inner membrane (Lange et al, 1999). Monosomy of chromosome
18 and deletions of 18q are almost certainly more frequent in MDS
(Berger et al, 1992) than protoporphyrin-induced photosensitivity,
which suggests either that additional factors to decrease enzyme
activity are required, and are only present in a proportion of those
with one FECH allele, or that increased erythrocyte free
protoporphyrin concentrations, insuf®ciently high or persistent to
cause overt photosensitivity, are more frequent in MDS than
appreciated.
Our ®ndings may provide a general explanation for the
association with MDS of other late onset cases of EPP. In two of
®ve other patients with EPP and MDS, bone marrow cytogenetic
studies showed deletions of chromosome 18q and, in one of these,
allogeneic bone marrow transplantation returned the porphyrin
pro®le to normal (Lim et al, 1992). The karyotype was either
normal or not examined in the other three patients. As
microdeletions and other mutations in hematopoietic cells are
common in MDS (Mufti, 1992), these patients may also have
acquired a null FECH allele. Any future patients with late onset
EPP should be screened for underlying hematologic disease and
FECH mutations that are restricted to the bone marrow.
Whether the association of late-onset CEP with MDS can be
explained by acquired mutation of the UROS gene remains to be
determined. Of the two cases reported, the bone marrow karyotype
was either not examined (Yamauchi and Kushibi, 1992) or showed
no abnormalities (Ibbotson et al, 1998). The UROS gene is located
on chromosome 10q, which is rarely deleted in MDS (Heim,
1992). In order to reach the very low enzyme activities found in
autosomal recessive CEP (Fontanellas et al, 1996), both UROS
alleles would need to be abnormal in the hematopoietic cells of
patients with CEP and MDS. Possible mechanisms include somatic
mutation in the hematopoietic cells of an individual heterozygous
for a germline UROS mutation, analogous to the mechanism
postulated for late onset of another autosomal recessive porphyria
associated with polycythaemia (Akagi et al, 2000); somatic mutation
of both alleles with at least one mutation retaining some UROS
function; or somatic mutation of one allele combined with
chromosome 10 monosomy or disomy.
In addition to mutation of either the FECH or UROS gene in
hematopoietic cells, expansion of the defective clone is required. In
MDS, this occurs as part of the neoplastic process (Heaney and
Golde, 1999). At present, there is no evidence that somatic
mutation in hematopoietic stem cells of any of the genes for heme
biosynthesis can initiate clonal expansion but analysis of the relevant
genes in genomic DNA from bone marrow would seem worth-
while in any patient with late-onset erythropoietic porphyria in
whom germline mutation does not provide a complete explanation
for their disease.
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